GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (STU:CDG) » Definitions » Gross Margin %

Acorda Therapeutics (STU:CDG) Gross Margin % : 81.73% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Acorda Therapeutics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Acorda Therapeutics's Gross Profit for the three months ended in Mar. 2024 was €15.3 Mil. Acorda Therapeutics's Revenue for the three months ended in Mar. 2024 was €18.7 Mil. Therefore, Acorda Therapeutics's Gross Margin % for the quarter that ended in Mar. 2024 was 81.73%.


The historical rank and industry rank for Acorda Therapeutics's Gross Margin % or its related term are showing as below:

STU:CDG' s Gross Margin % Range Over the Past 10 Years
Min: 68.4   Med: 79.61   Max: 87.01
Current: 86.38


During the past 13 years, the highest Gross Margin % of Acorda Therapeutics was 87.01%. The lowest was 68.40%. And the median was 79.61%.

STU:CDG's Gross Margin % is ranked better than
95.74% of 986 companies
in the Drug Manufacturers industry
Industry Median: 46.51 vs STU:CDG: 86.38

Acorda Therapeutics had a gross margin of 81.73% for the quarter that ended in Mar. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Acorda Therapeutics was 0.10% per year.


Acorda Therapeutics Gross Margin % Historical Data

The historical data trend for Acorda Therapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acorda Therapeutics Gross Margin % Chart

Acorda Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 81.89 78.09 68.40 74.42 87.01

Acorda Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.47 89.67 87.78 85.26 81.73

Competitive Comparison of Acorda Therapeutics's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acorda Therapeutics's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Acorda Therapeutics's Gross Margin % falls into.



Acorda Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Acorda Therapeutics's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=93.9 / 107.869
=(Revenue - Cost of Goods Sold) / Revenue
=(107.869 - 14.014) / 107.869
=87.01 %

Acorda Therapeutics's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=15.3 / 18.666
=(Revenue - Cost of Goods Sold) / Revenue
=(18.666 - 3.411) / 18.666
=81.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Acorda Therapeutics  (STU:CDG) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Acorda Therapeutics had a gross margin of 81.73% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Acorda Therapeutics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Acorda Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Acorda Therapeutics (STU:CDG) Business Description

Traded in Other Exchanges
Address
2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.

Acorda Therapeutics (STU:CDG) Headlines

No Headlines